ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Files An 8-K Results of Operations and Financial Condition

Item2.02.

On March30, 2017, Aldeyra Therapeutics, Inc. (Aldeyra) issued a
press release and is holding a conference call regarding its
financial results for the year ended December31, 2016. The press
release is furnished as Exhibit 99.1 to this Current Report on
Form8-K and is
incorporated by reference herein.

Various statements
to be made during the conference call are forward-looking
statements under the securities laws, including, but not limited
to, statements regarding Aldeyras plans for its product
candidates. In some cases, you can identify forward looking
statements by terms such as, but not limited to, may, might,
will, objective, intend, should, could, can, would, expect,
believe, anticipate, project, target, design, estimate, predict,
potential, plan or the negative of these terms, and similar
expressions intended to identify forward-looking statements.Such
forward- looking statements are based upon current expectations
that involve risks, changes in circumstances, assumptions and
uncertainties.

Aldeyra is at an
early stage of development and may not ever have any products
that generate significant revenue. Important factors that could
cause actual results to differ materially from those reflected in
Aldeyras forward-looking statements include, among others, the
timing of enrollment, commencement and completion of Aldeyras
clinical trials, the timing and success of preclinical studies
and clinical trials conducted by Aldeyra and its development
partners; the ability to obtain and maintain regulatory approval
to conduct clinical trials and to commercialize Aldeyras product
candidates, and the labeling for any approved products; the
scope, progress, expansion, and costs of developing and
commercializing Aldeyras product candidates; the size and growth
of the potential markets for Aldeyras product candidates and the
ability to serve those markets; Aldeyras expectations regarding
Aldeyras expenses and revenue, the sufficiency of Aldeyras cash
resources and needs for additional financing; the rate and degree
of market acceptance of any of Aldeyras product candidates;
Aldeyras expectations regarding competition; Aldeyras anticipated
growth strategies; Aldeyras ability to attract or retain key
personnel; the anticipated trends and challenges in Aldeyras
business and the market in which it operates; and other factors
that are described in the Risk Factors and Managements Discussion
and Analysis of Financial Condition and Results of Operations
sections of Aldeyras Annual Report on Form 10-K for the year ended
December31, 2015 and Aldeyras Quarterly Report on Form 10-Q for
the quarter ended September30, 2016, which are on file with the
Securities and Exchange Commission (SEC) and available on the
SECs website at www.sec.gov. Additional information will also be
set forth in those sections of Aldeyras Annual Report on Form
10-K for the year ended December31, 2016, which will be filed
with the SEC in the first quarter of 2017.